TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33151978

Group type: EXPERIMENTAL
Intervention: Independent surgical team for wound closure
Number of subjects: 144

Group type: COMPARATOR
Intervention: Main surgical team for wound closure
Number of subjects: 144
Study: 33152061

Group type: EXPERIMENTAL
Intervention: Highest tertile of Mediterranean Diet Adherence Screener score
Number of subjects: 1301

Group type: EXPERIMENTAL
Intervention: Maintaining or improving DAI over follow-up (over-resilience)
Number of subjects: 1301

Group type: EXPERIMENTAL
Intervention: Unintentional weight loss as acute stressor
Number of subjects: 1301

Group type: EXPERIMENTAL
Intervention: Hospitalization as acute stressor
Number of subjects: 1301
Study: 33152282

Group type: EXPERIMENTAL
Intervention: Angiogenesis inhibitors
Number of subjects: 0
Study: 33152715

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33152759

Group type: EXPERIMENTAL
Intervention: KMT2D mutations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wild-type KMT2D
Number of subjects: 0
Study: 33153453

Group type: EXPERIMENTAL
Intervention: Enhanced recovery protocols (ERPs) for THA/TKA
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 186
Study: 33153461

Group type: EXPERIMENTAL
Intervention: Standardized Multimodal Intervention (MMI) for 24 weeks
Number of subjects: 390
Study: 33153503

Group type: EXPERIMENTAL
Intervention: Deep transcranial magnetic stimulation (dTMS); specific dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33153580

Group type: EXPERIMENTAL
Intervention: Complicated carotid artery plaques (CAP) in patients with cryptogenic stroke (CS) ipsilateral to the infarct
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Complicated carotid artery plaques (CAP) in patients with cryptogenic stroke (CS) contralateral to the infarct
Number of subjects: 196

Group type: COMPARATOR
Intervention: Complicated carotid artery plaques (CAP) in patients with cryptogenic stroke (CS) compared to cardioembolic or small vessel stroke (CES/SVS)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Complicated carotid artery plaques (CAP) in patients with cryptogenic stroke (CS) compared to large artery stroke (LAS)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Lipid-rich and/or necrotic cores in ipsilateral CAP in patients with cryptogenic stroke (CS) compared to cardioembolic or small vessel stroke (CES/SVS)
Number of subjects: 196
Study: 33153629

Group type: EXPERIMENTAL
Intervention: lenzilumab 600 mg intravenously for three doses
Number of subjects: 39

Group type: COMPARATOR
Intervention: untreated (control)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: lenzilumab
Number of subjects: 39
Study: 33153727

Group type: EXPERIMENTAL
Intervention: Apararenone (320 mg on day 2, 20 mg/d on days 3-15) with Midazolam (2 mg on days 1 and 15)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Apararenone (40 mg/d on days 8-11, 10 mg/d on days 12-27) with Warfarin (25 mg on days 1 and 21)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Apararenone (160 mg on day 11, 10 mg/d on days 12-28) with Digoxin (0.5 mg on days 1 and 24)
Number of subjects: 56
Study: 33153960

Group type: EXPERIMENTAL
Intervention: OGTT (Oral Glucose Tolerance Test)
Number of subjects: 131
Study: 33154028

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 0
Study: 33154049

Group type: EXPERIMENTAL
Intervention: Respiratory function parameters
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Pneumonia-related mortality
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Longitudinal data for prognostic models
Number of subjects: 500
Study: 33154057

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel plus gemcitabine (nab-P+Gem) chemotherapy plus split-course SBRT
Number of subjects: 0
Study: 33154417

Group type: EXPERIMENTAL
Intervention: Faecal volatile organic compounds (VOCs) analysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (children discharged alive)
Number of subjects: 0
Study: 33154826

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) with low pre-therapeutic serum GGT levels (< 29 U/L)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (NAC) with high pre-therapeutic serum GGT levels (≥ 29 U/L)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 129
Study: 33154953

Group type: EXPERIMENTAL
Intervention: Intranasal application of nan
Number of subjects: 0
Study: 33155163

Group type: EXPERIMENTAL
Intervention: PF-5190457
Number of subjects: 47
Study: 33155938

Group type: EXPERIMENTAL
Intervention: macitentan 10 mg/day
Number of subjects: 44

Group type: COMPARATOR
Intervention: bosentan 250 mg/day
Number of subjects: 44
Study: 33156107

Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation (CBA)
Number of subjects: 120
Study: 33156244

Group type: EXPERIMENTAL
Intervention: Blood Alcohol Concentration (BAC) screening
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: CRAFFT screening
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Urine Drug Screen (UDS)
Number of subjects: 300
Study: 33156398

Group type: EXPERIMENTAL
Intervention: Fiberoptic Flexible Endoscopic Evaluation of Swallowing (FEES) examination
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Univariate and multivariable analyses
Number of subjects: 213
Study: 33156465

Group type: EXPERIMENTAL
Intervention: Clinically relevant postoperative pancreatic fistula (CR-POPF)
Number of subjects: 283

Group type: COMPARATOR
Intervention: No CR-POPF
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: CR-POPF
Number of subjects: 283
Study: 33156829

Group type: EXPERIMENTAL
Intervention: Higher reward
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Task-related activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endogenous responses
Number of subjects: 0
Study: 33156849

Group type: EXPERIMENTAL
Intervention: Delayed mobilization (≥36h)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Early mobilization (<36h)
Number of subjects: 306
Study: 33156982

Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) 100/62.5/25µg
Number of subjects: 10355

Group type: COMPARATOR
Intervention: Fluticasone Furoate/Vilanterol (FF/VI) 100/25µg
Number of subjects: 10355

Group type: COMPARATOR
Intervention: Umeclidinium/Vilanterol (UMEC/VI) 62.5/25µg
Number of subjects: 10355

Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)
Number of subjects: 10355

Group type: COMPARATOR
Intervention: Fluticasone Furoate/Vilanterol (FF/VI) and Umeclidinium/Vilanterol (UMEC/VI)
Number of subjects: 10355
Study: 33157081

Group type: EXPERIMENTAL
Intervention: Biomarkers of COVID-19 severity in patients with type 2 diabetes
Number of subjects: 0
Study: 33157979

Group type: EXPERIMENTAL
Intervention: FLT-PET imaging
Number of subjects: 0
Study: 33158499

Group type: EXPERIMENTAL
Intervention: Postoperative troponin increases
Number of subjects: 114
Study: 33158766

Group type: EXPERIMENTAL
Intervention: SADI-S
Number of subjects: 42

Group type: COMPARATOR
Intervention: DS
Number of subjects: 42
Study: 33158801

Group type: EXPERIMENTAL
Intervention: Highly processed (HP) foods
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Savory food intake in the HP condition
Number of subjects: 46

Group type: COMPARATOR
Intervention: Minimally processed (MP) foods
Number of subjects: 46
Study: 33158819

Group type: EXPERIMENTAL
Intervention: Integrated intervention (INT) which includes pharmacotherapy and a hybrid of behavioural support delivered by trained healthcare practitioners (HCPs) and a web-based application.
Number of subjects: 5

Group type: COMPARATOR
Intervention: Usual care (UC) which consists of standard community/hospital based NHS smoking support.
Number of subjects: 5
Study: 33158947

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33159213

Group type: EXPERIMENTAL
Intervention: Initiation of treatment at the time of diagnosis in males with X-linked Alport syndrome
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initiation of treatment at the time of diagnosis in males and females with autosomal recessive Alport syndrome
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Starting treatment at the onset of microalbuminuria in females with X-linked Alport syndrome
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Starting treatment at the onset of microalbuminuria in males and females with autosomal dominant Alport syndrome
Number of subjects: 0
Study: 33159216

Group type: EXPERIMENTAL
Intervention: Temsirolimus 25 mg IV weekly and Erlotinib 100 mg orally daily (RP2D)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Temsirolimus 15 mg IV weekly and Erlotinib 100 mg orally daily (starting dose)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Temsirolimus and Erlotinib combination
Number of subjects: 44
Study: 33159275

Group type: EXPERIMENTAL
Intervention: Reduced intensity conditioning (RIC) with post-transplantation cyclophosphamide (PTCy) and mycophenolate mofetil and tacrolimus for GVHD prophylaxis.
Number of subjects: 25
Study: 33159365

Group type: EXPERIMENTAL
Intervention: Bisantrene (250 mg/m2)
Number of subjects: 10
Study: 33159841

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonist
Number of subjects: 0

Group type: COMPARATOR
Intervention: Background therapy
Number of subjects: 0
Study: 33160031

Group type: EXPERIMENTAL
Intervention: Fasting serum copeptin measured by high-sensitivity ELISA
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (patients without aPAD)
Number of subjects: 112
Study: 33160321

Group type: EXPERIMENTAL
Intervention: Observational cohort study
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Cognitive evaluation using the 10-point Cognitive Screener (10-CS)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Frailty assessment using Fried index score
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Nutritional assessment (body composition assessment, global subjective assessment, dietary intake)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Comorbidities assessment using Charlson comorbidity index
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Biochemical markers including FGF-23 and Klotho
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Observational follow-up for at least 12 months
Number of subjects: 200
Study: 33160339

Group type: EXPERIMENTAL
Intervention: MeTree risk assessment program
Number of subjects: 1889
Study: 33160342

Group type: EXPERIMENTAL
Intervention: Simulator-based training session utilizing a novel low-cost simulator made with gelatin, water, and psyllium fiber for three hours.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Simulator-based training session
Number of subjects: 60
Study: 33160343

Group type: EXPERIMENTAL
Intervention: Kinesiophobia (measured by the Tampa Scale)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Early functional performance (measured by the Iowa Level of Assistance scale)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Preoperative functional ability (measured by the Western Ontario and McMaster Osteoarthritis Index)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Demographics (age, sex, body mass index)
Number of subjects: 269
Study: 33160701

Group type: EXPERIMENTAL
Intervention: 24 h Urinary magnesium concentration (24 h UMg)
Number of subjects: 3179

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 3179
Study: 33160700

Group type: EXPERIMENTAL
Intervention: COVID-19 survivors
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: COVID-19 survivors with weight loss
Number of subjects: 213
Study: 33160848

Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET) imaging
Number of subjects: 213

Group type: COMPARATOR
Intervention: Conventional imaging
Number of subjects: 213
Study: 33161007

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) applied at home, 2-3 times/day during bowel regimen
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) during bowel routine
Number of subjects: 5
Study: 33161013

Group type: EXPERIMENTAL
Intervention: FDG-PET-based dose-painting technique with SIB-IMRT and concomitant Cisplatin after 2 cycles of induction chemotherapy.
Number of subjects: 29
Study: 33161160

Group type: EXPERIMENTAL
Intervention: Duodenal fluid microbiome of patients with PDAC
Number of subjects: 308

Group type: COMPARATOR
Intervention: Duodenal fluid microbiome of control subjects and patients with pancreatic cyst(s)
Number of subjects: 308
Study: 33161240

Group type: EXPERIMENTAL
Intervention: Emactuzumab (IV administration, 900 to 2000 mg every two weeks in dose-escalation phase, optimal biological dose of 1000 mg in dose-expansion phase)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Emactuzumab
Number of subjects: 63
Study: 33161258

Group type: EXPERIMENTAL
Intervention: Cochlear implant (Slim Modiolar) with bimodal stimulation (cochlear implant and hearing aid in contralateral ear) for 6-months postimplant
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Bimodal condition (cochlear implant and hearing aid)
Number of subjects: 100
Study: 33161492

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 422

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 422
Study: 33161777

Group type: EXPERIMENTAL
Intervention: Galvanic current-induced vasodilation (CIV) in patients under low-dose aspirin (ASA; ≤ 500 mg/day)
Number of subjects: 822

Group type: COMPARATOR
Intervention: Galvanic current-induced vasodilation (CIV) in patients not under low-dose aspirin (ASA; ≤ 500 mg/day)
Number of subjects: 822
Study: 33161846

Group type: EXPERIMENTAL
Intervention: SAA (serum amyloid A) levels on admission
Number of subjects: 650
Study: 33161899

Group type: EXPERIMENTAL
Intervention: CD4-independent score of ≥ 4
Number of subjects: 2838

Group type: COMPARATOR
Intervention: WHO eligibility criteria (EC)
Number of subjects: 2838

Group type: EXPERIMENTAL
Intervention: CD4-independent score categorized into low (< 4), moderate (4-6), and high risk (≥ 7)
Number of subjects: 2838

Group type: EXPERIMENTAL
Intervention: CD4-dependent score
Number of subjects: 2838
Study: 33163109

Group type: EXPERIMENTAL
Intervention: Nintendo Wii Fit Plus™ home-based exercise program, 3 times a week for 30 min for 24 weeks
Number of subjects: 0
Study: 33163394

Group type: EXPERIMENTAL
Intervention: Ganglioside monosialic acid (GM1)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Utidelone plus capecitabine
Number of subjects: 55
Study: 33163408

Group type: EXPERIMENTAL
Intervention: Ablation therapy
Number of subjects: 0
Study: 33163984

Group type: EXPERIMENTAL
Intervention: Antibody positivity defined as a dual-positive response against both the receptor-binding domain and nucleocapsid proteins of SARS-CoV-2.
Number of subjects: 15771

Group type: EXPERIMENTAL
Intervention: Antibody surveillance in children during 2020.
Number of subjects: 15771

Group type: EXPERIMENTAL
Intervention: Antibody prevalence from April 2020.
Number of subjects: 15771

Group type: EXPERIMENTAL
Intervention: Transmission in children with virus-positive family members.
Number of subjects: 15771

Group type: EXPERIMENTAL
Intervention: Asymptomatic positive children.
Number of subjects: 15771

Group type: EXPERIMENTAL
Intervention: Antibody frequency in newborns.
Number of subjects: 15771
Study: 33164349

Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg SC every 2 weeks (Q2W)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Switching from IV to SC sarilumab 200 mg SC Q2W
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Continuing sarilumab 200 mg SC Q2W
Number of subjects: 175
Study: 33164633

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy
Number of subjects: 12764

Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 12764

Group type: EXPERIMENTAL
Intervention: Age ≥65 years and use of diuretics at discharge
Number of subjects: 12764
Study: 33164985

Group type: EXPERIMENTAL
Intervention: Subcutaneous adipose tissue oxygen partial pressure (pO2) measurement in MHL, MHO, and MUO groups.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Adipose tissue pO2 measurement.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Plasma PAI-1 concentration measurement.
Number of subjects: 46

Group type: COMPARATOR
Intervention: Plasma concentrations of other cytokines and chemokines measurement.
Number of subjects: 46
Study: 33164993

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avacopan
Number of subjects: 0
Study: 33165001

Group type: EXPERIMENTAL
Intervention: Low-dose haemodialysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incremental haemodialysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deintensification of haemodialysis treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-dose haemodialysis
Number of subjects: 0
Study: 33165027

Group type: EXPERIMENTAL
Intervention: 5% albumin
Number of subjects: 18229

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 18229
Study: 33165120

Group type: EXPERIMENTAL
Intervention: Assessment of Perceived Access to Care (APAC)
Number of subjects: 1004
Study: 33165755

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (79.2%)
Number of subjects: 1021

Group type: EXPERIMENTAL
Intervention: Antivirals (67.6%)
Number of subjects: 1021

Group type: COMPARATOR
Intervention: All-cause mortality
Number of subjects: 1021

Group type: COMPARATOR
Intervention: Age, hypertension, obesity, renal insufficiency, any immunosuppressive disease, O2 saturation < 92%, elevated C reactive protein
Number of subjects: 1021
Study: 33165773

Group type: EXPERIMENTAL
Intervention: Roxadustat (100 mg single dose)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Roxadustat (100 mg single dose) after dialysis (P1)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Roxadustat (100 mg single dose) before dialysis (P2)
Number of subjects: 34
Study: 33166419

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 4740

Group type: COMPARATOR
Intervention: Insulin detemir
Number of subjects: 4740

Group type: COMPARATOR
Intervention: Insulin glargine and insulin detemir
Number of subjects: 4740
Study: 33167024

Group type: EXPERIMENTAL
Intervention: Obinutuzumab-ibrutinib induction for 9 months followed by ibrutinib for 6 additional months in patients with complete remission and BM MRD <0.01% (n = 10)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Fludarabine/cyclophosphamide-obinutuzumab immunochemotherapy for 4 cycles in patients with partial remission and/or BM MRD ≥0.01% (n = 120)
Number of subjects: 135
Study: 33167773

Group type: EXPERIMENTAL
Intervention: Metformin (2 g/day)
Number of subjects: 20
Study: 33167995

Group type: COMPARATOR
Intervention: Highest quintile of organic food (OF) consumption
Number of subjects: 33256

Group type: EXPERIMENTAL
Intervention: Increment of 5% in the proportion of OF in the diet
Number of subjects: 33256
Study: 33168134

Group type: EXPERIMENTAL
Intervention: Reprogramming of bone marrow myeloid progenitor cells in patients with severe coronary artery disease
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (subjects without atherosclerosis)
Number of subjects: 26
Study: 33168363

Group type: EXPERIMENTAL
Intervention: Epicardial adipose tissue (EAT) volume assessed by computed tomography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proteome of EAT assessed by SWATH-MS mass spectrometry
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mediastinal and subcutaneous adipose tissue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Circulating and local adipose tissue-derived biomarkers of CAD
Number of subjects: 0
Study: 33168556

Group type: EXPERIMENTAL
Intervention: Qualitative interviews with older adults and caregivers
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Web-based survey for interdisciplinary health and social care providers
Number of subjects: 30
Study: 33168612

Group type: EXPERIMENTAL
Intervention: Nifurtimox (NF) treatment; children received 10 to 15 mg/kg/day for 60 to 90 days; adults received 8 to 10 mg/kg/day for 30 days
Number of subjects: 320
Study: 33168654

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 4827

Group type: COMPARATOR
Intervention: Standard diabetes support and education (DSE)
Number of subjects: 4827
Study: 33168818

Group type: EXPERIMENTAL
Intervention: Co-administration of unconjugated antibody with panitumumab-IRDye800CW
Number of subjects: 0

Group type: COMPARATOR
Intervention: Panitumumab-IRDye800CW alone
Number of subjects: 0
Study: 33169372

Group type: EXPERIMENTAL
Intervention: Carpal tunnel release surgery in people with diabetes (n=27)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Carpal tunnel release surgery in people without diabetes (n=30)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both groups (people with and without diabetes)
Number of subjects: 66
Study: 33169671

Group type: EXPERIMENTAL
Intervention: Lung-protective ventilation with low tidal volume (median 6.3 mL/kg predicted bodyweight, IQR 5.7-7.1)
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP)
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Driving pressure
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Adjunctive treatments for refractory hypoxaemia
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Ventilator-free days at day 28
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Duration of ventilation
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Duration of ICU and hospital stay
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 553
Study: 33169839

Group type: EXPERIMENTAL
Intervention: Intravenous oxytocin
Number of subjects: 7817
Study: 33169859

Group type: EXPERIMENTAL
Intervention: Married patients
Number of subjects: 2378

Group type: EXPERIMENTAL
Intervention: Divorced patients
Number of subjects: 2378

Group type: EXPERIMENTAL
Intervention: Widowed patients
Number of subjects: 2378

Group type: EXPERIMENTAL
Intervention: Health perception quartiles
Number of subjects: 2378

Group type: COMPARATOR
Intervention: Secondary or primary education
Number of subjects: 2378

Group type: COMPARATOR
Intervention: Presence of depression
Number of subjects: 2378